Asymmetric dimethylarginine is not associated with subendocardial viability ratio in Rheumatoid Arthritis

Rheumatoid Arthritis (RA) is associated with increased cardiovascular (CV) mortality and reduced life expectancy predominantly due to increased rates of acute coronary syndromes including unrecognized myocardial infractions [1]. The increased CV burden in this population has prompted rheumatologists and cardiologists to a more early and vigilant screening for CV risk stratification even in asymptomatic patients. Asymmetric dimethylarginine (ADMA) and subendocardial viability ratio (SEVR) represent non-invasive methods of assessing endothelial dysfunction and coronary microvascular perfusion to subendocardium respectively, two pivotal players in the development of CV disease and myocardial ischemia